FDA approves first immunotherapy for recurrent respiratory papillomatosis

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year

Shanmuga Hospital commissions advanced PH impedance and manometry system

This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.

FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients

Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Xspray Pharma licenses patent rights to Handa Therapeutics, secures royalty agreement

Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025

AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease

Phase 1 dosing is expected to finish by the end of 2025